Retrospective studies on platinum-based chemotherapy in patients with resected homologous recombination-deficient PDAC
| Disease setting | Mutations | Design | Therapy line | Therapy | Number of pts. | mDFS | mOS | Reference |
| Resected | Group 1: BRCA1/2 or PALB2 Group 2: ATM/ATR/ATRX Group 3: BAP1, BARD1, BRIP1, CHEK1/2, RAD50/51/51B or FANCA/C/D2/E/F/G/L | Retrospective | Adjuvant | Platinum-containing Platinum-naïve | Total: 377 HRD: 63 HRP: 314 | n.a. | HRD+platinum (n=49): 4.53 y HRD-platinum (n=14): 1.8 y HRP+platinum (n=220): 2.96 y HRP-platinum (n=94): 3.09 y | 83 |
| Resected | BRCA1 BRCA2 | Retrospective | n.a. | n.a. | Total: 20 | 13 m | n.a. | 84 |
| Resected | BRCA1 BRCA2 PALB2 | Retrospective | Various | Platinum-containing Platinum-naïve | Total: 96 HRD: 32 HRP: 64 | HRD+perioperative platinum: 19.9 m HRP+perioperative platinum: 11.7 m | HRD+perioperative platinum: not reached HRP+perioperative platinum: 23.1 m | 89 |
| Resected | BRCA1 (n=4) gBRCA2 (n=18) | Retrospective | Adjuvant | Platinum-containing Platinum-naïve | Total: 127 HRD: 22 HRP: 105 | HRD+platinum (n=10): 31 m HRD-platinum (n=8): 17.8 m HRP+platinum: 33 m HRP-platinum: 28 m | 130 |
HRD, homologous recombination-deficient; HRP, homologous recombination-proficient; m, month; n.a., not applicable; pts., patients; y, year.